ERBB2 and breast cancer: This is a potential confounder, particularly for subtypes like HER2+, where treatment advances have been substantial.50,53,54,59 While we accounted for some of these variables by including stage, age, and BC subtype in the multivariable analyses, these variables serve only as proxies for treatment.